CABINET Subgroup Analysis
CABINET: Subgroup Analysis of Cabozantinib vs Placebo After ≥1 Prior Line of Therapy in Advanced Extrapancreatic Neuroendocrine Tumors Arising in GI Tract

Released: February 07, 2025

Expiration: August 06, 2025

Activity

Progress
1
Course Completed